WIDEN by Dixit

Casa
Italia
Turin
WIDEN by Dixit

Network digital solutions for medical imaging Dixit is a company specialized in providing advanced technology solutions to support clinical trial organizers.

It focuses on managing the sharing of medical images within the network of participating clinical sites, the quality control of those images and the associated reporting. With WIDEN, Dixit ensures compliance with protocol, data quality, security and speed of information exchange between physicians at different locations, and it improves the trial organization by allowing the control on the entire workflow and facilitating the achievement of the trial endpoints. WIDEN (Web-based Imaging and Diagnosis Exchange Network) is the flagship product offered by Dixit. It is designed for multicenter clinical trials in which imaging is used to guide treatment in real time based on the sensitivity of each individual patient, constituting a step towards personalized medicine. The real-time review and adaptation of therapy, implemented thanks to WIDEN’s functionality, are crucial to treat diseases with a higher success rate.

06/10/2025

WIDEN is in Barcelona for EANM 2025!

WIDEN is participating in the European Association of Nuclear Medicine (EANM) 2025, taking place in Barcelona.

From cutting-edge innovation to meaningful collaboration, EANM is a key event for the nuclear medicine community - and we’re proud to be part of it once again.

Come visit us at our booth 22 to discover how WIDEN is shaping the future of nuclear medicine through advanced data-driven solutions.

Let’s connect, share insights, and build the future together.�

29/09/2025

We look forward to meeting you at the EANM Congress to be held October 4-8, 2025 in Barcelona.
Come and visit us at booth 22.

Let's grow together.

16/09/2025

New convincing results in PET for lymphoma and myeloma require the highest accuracy in PET review and the analysis of complex radiomic indexes. Widen is here for this!

12/09/2025

We are pleased to announce that WIDEN today is participating in the 10th international workshop on PET in lymphoma and myeloma (PILM 2025) scheduled to take place in Menton from 12 to 13 September 2025.

Come and visit us at our booth.

24/06/2025

It was a pleasure to attend the 18th ICML international congress in Lugano, a landmark for innovation in lymphoma research.

On 18 June, we held a private session entitled: “Translating Imaging Biomarkers into Clinical Practice Using the WIDEN Platform”.
It was an inspiring meeting, which allowed us to exchange views with international KOLs on the role of PET as a key tool for patient stratification and early assessment of response to therapy.

Together, we envisage a roadmap towards the adoption of imaging biomarkers in clinical practice, with the aim of improving the personalisation of treatments in lymphoma patients.
We are proud of the progress of the WIDEN platform and the opportunity to contribute to an increasingly data-driven medicine.

16/06/2025

We are pleased to announce that WIDEN will participate in the 18-ICML conference, scheduled to take place in Lugano from 17 to 21 June 2025.
On June 18th, we will hold a lunch session about: “Translating Imaging Biomarkers into Clinical Practice Using the WIDEN Platform”.
The presentation, which will take place privately at the International Conference of Malignant Limphoma venue, is an important opportunity to discuss with experts in the field how our platform can contribute to the effective integration of imaging biomarkers into clinical practice.
We are excited to share our progress and our commitment to build meaningful collaborations in the field of hematology.

07/03/2025

WIDEN is… Faster!

Speed at the service of clinical innovation.

With WIDEN, we optimise the entire image and protocol management process to speed up every stage of your project.
Here's how:

- Ultra-fast uploads and downloads to minimise upload times;
- Automated workflow management, image and protocol QA, integrated notification system;
- Centralised, real-time reporting to achieve consensus between multiple reviewers without delays.
The outcome? Reduced time-to-market thanks to simple scaling to a large number of sites and real time control on the eligibility of recruited patients for the final data analysis, allowing you to publish results and request approval in record time

With WIDEN, the future of clinical trial image management is already here!

21/02/2025

Piergiorgio, co-founder of diXit, is currently Research Director at the Italian National Institute of Nuclear Physics (INFN), and winemaker at “La Stradina” (Gattinara, Italy).
He started his career as a particle physicist, and is one of the founders of the ALICE project at the CERN LHC (Geneva, Switzerland), for which he coordinated the early development of the successful computing model, based on the use of GRIDs for the analysis of large quantities of distributed data.
In the early 2000s, he founded the medical imaging group at INFN, Torino, which over the years has achieved two relevant results: the development of a Computer Assisted Detection system for lung nodules in chest CTs, successfully validated in a clinical setting, and the construction of the INSIDE PET detector for online range verification in Particle Therapy, presently undergoing a clinical trial at CNAO (Pavia, Italy).

15/02/2025

🌐 Discover WIDEN by Dixit: the digital revolution for imaging-based clinical trials 📈

WIDEN (Web-based Image and Diagnosis Exchange Network) accelerates every aspect of clinical image management, from ultra-fast uploads/downloads to secure centralised real-time review. With features such as automated quality control, custom workflow management with integrated notifications, WIDEN allows trial scaling to a large number of sites, simplifies data access and enables faster time-to-market. A complete, user friendly and secure platform that efficiently tackles clinical challenges.

Learn more 👉 WIDEN by Dixit: https://www.dixitsolutions.com/widen

04/02/2025

Today, on International Cancer Day, we reflect on the importance of scientific and technological research in improving the lives of people facing this disease.

WIDEN is glad of its contribution in supporting medical researchers.
🔬 In 2007, we began the development to handle the workflow and quality assurance of a multi-centre clinical trial based on the use of PET/CT to assess the response to therapy in Hodgkin's Lymphoma.
💻 In 2008, the first beta version of WIDEN was used in 3 clinical trials to optimise the workflow related to imaging handling and diagnosis consensus definition.
🌟 In 2011, with the incorporation of Dixit, we embarked on a journey of continuous innovation, collaborating with public and private organisations to improve global health.

Our mission is clear: to use technology in maximising the efficiency of medical imaging in cancer diagnosis, treatment and research. Today, we join the global community in raising awareness on the importance of research in prevention, diagnosis, therapy and support for people affected by cancer.

31/01/2025

WIDEN by Dixit: the 360° clinical image management solution

In an industry where accuracy and speed are everything, WIDEN by Dixit offers a secure, integrated platform for clinical image management in trials. With rapid upload and customised workflows, real-time quality assurance and centralised review, WIDEN simplifies every step of the process, enabling faster decisions and providing reliable results.

Learn more about how WIDEN supports clinical innovation here 👉 WIDEN by Dixit: https://www.dixitsolutions.com/widen

17/01/2025

The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials

Positron emission tomography (PET) has been a widely used tool in oncology for staging lymphomas for a long time. Recently, several large clinical trials demonstrated its effectiveness in therapy management during treatment, paving the way to personalized medicine. In doing so, the traditional PET reporting, based on the extent of disease, has been complemented with a discrete scale that takes into account tumour metabolism. However, due to several technical, physical and biological limitations in the use of PET uptake as a biomarker, stringent rules have been used in clinical trials to reduce the errors in its evaluation. In this manuscript we shortly describe the evolution in PET reporting, examine the main error sources in uptake measurement, and analyse the strategies the clinical trials applied to minimise them.

Learn more at: https://www.mdpi.com/2227-9059/4/4/26

Indirizzo

Via Agostino Da Montefeltro, 2
Turin
10134

Telefono

+393899454479

Sito Web

https://www.dixitsolutions.com/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando WIDEN by Dixit pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.